Brokerages expect Allogene Therapeutics Inc (NASDAQ:ALLO) to announce earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Allogene Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.54). The business is scheduled to issue its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.45). For the next year, analysts anticipate that the business will report earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Allogene Therapeutics.
Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.
In other Allogene Therapeutics news, insider Alison Moore sold 48,828 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here. 36.50% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Barclays PLC purchased a new position in Allogene Therapeutics during the fourth quarter valued at approximately $27,000. Legal & General Group Plc purchased a new position in Allogene Therapeutics during the fourth quarter valued at approximately $89,000. Partner Investment Management L.P. purchased a new position in shares of Allogene Therapeutics in the fourth quarter worth $135,000. NumerixS Investment Technologies Inc purchased a new position in shares of Allogene Therapeutics in the first quarter worth $136,000. Finally, Citigroup Inc. purchased a new position in shares of Allogene Therapeutics in the fourth quarter worth $152,000. 53.47% of the stock is currently owned by institutional investors and hedge funds.
Shares of ALLO stock traded down $0.21 during trading hours on Friday, reaching $26.40. The company had a trading volume of 320,634 shares, compared to its average volume of 517,616. The business has a fifty day moving average of $26.99. Allogene Therapeutics has a one year low of $21.67 and a one year high of $35.55. The firm has a market capitalization of $3.23 billion and a price-to-earnings ratio of -4.01. The company has a current ratio of 17.48, a quick ratio of 17.48 and a debt-to-equity ratio of 0.05.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Article: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.